Quantitative analysis revealed a ~46.3% reduction in tau Ser404 deposition in the CA3 region of Avn–C-treated Tg2576 mice versus vehicles (p < 0.01, n = 5), indicating that Avn-C effectively limits tau pathology when administered from the early stages of AD (Figure 3b,c). The gene discussed is MAPT; the disease is Alzheimer disease.